HF
ACRS icon

HRT Financial’s Aclaris Therapeutics ACRS Stock Holding History

HRT Financial’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,286
Closed -$26K – 2509
2025
Q1 		$26K Buy
+17,286
New +$36.9K ﹤0.01% 2281
2024
Q3 		– Sell
-81,005
Closed -$89K – 2331
2024
Q2 		$89K Buy
+81,005
New +$95.2K ﹤0.01% 1776
2023
Q1 		– Sell
-45,535
Closed -$717K – 2417
2022
Q4 		$717K Buy
+45,535
New +$733K 0.01% 1194
2021
Q2 		– Sell
-152,119
Closed -$3.83M – 2766
2021
Q1 		$3.83M Buy
+152,119
New +$2.97M 0.04% 348
2020
Q1 		– Sell
-49,323
Closed -$93K – 721
2019
Q4 		$93K Buy
+49,323
New +$81.7K ﹤0.01% 1036

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

HRT Financial's ACRS Position: Q2 2025 in Review

HRT Financial sold out of Aclaris Therapeutics (ACRS) in Q2 2025, closing a stake of 17,286 shares — an estimated $26K sold.

HRT Financial first reported a position in ACRS in Q4 2019 and held it in 5 quarters. The position peaked at $3.83M in Q1 2021. 96 funds tracked by Wall St. Rank hold ACRS as of Q2 2025.

  • HRT Financial reported no remaining Aclaris Therapeutics position as of Q2 2025 after selling out during the quarter.
  • HRT Financial sold 17,286 Aclaris Therapeutics shares in Q2 2025, an estimated $26K.
  • HRT Financial first reported a position in Aclaris Therapeutics in Q4 2019 and held it in 5 quarters.
  • HRT Financial's Aclaris Therapeutics position peaked at $3.83M in Q1 2021.
  • 96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2025.

Based on HRT Financial's 13F filing for Q2 2025, filed 14 Aug 2025.